Art
J-GLOBAL ID:201002238278357405   Reference number:10A1546033

Clinical Path for mFOLFOX6 Describing Criteria for Reduction and Suspension of Drugs

減量・休薬基準を明記したmFOLFOX6療法の試み
Author (16):
Material:
Volume: 37  Issue: 12  Page: 2588-2590  Publication year: Nov. 30, 2010 
JST Material Number: Z0938A  ISSN: 0385-0684  Document type: Article
Article type: 原著論文  Country of issue: Japan (JPN)  Language: JAPANESE (JA)
Thesaurus term:
Thesaurus term/Semi thesaurus term
Keywords indexed to the article.
All keywords is available on JDreamIII(charged).
On J-GLOBAL, this item will be available after more than half a year after the record posted. In addtion, medical articles require to login to MyJ-GLOBAL.
,...
Semi thesaurus term:
Thesaurus term/Semi thesaurus term
Keywords indexed to the article.
All keywords is available on JDreamIII(charged).
On J-GLOBAL, this item will be available after more than half a year after the record posted. In addtion, medical articles require to login to MyJ-GLOBAL.
,...
   To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=10A1546033&from=J-GLOBAL&jstjournalNo=Z0938A") }}
JST classification (2):
JST classification
Category name(code) classified by JST.
Tumors(=neoplasms)of digestive system  ,  Drug therapy(=pharmacotherapy)for tumors 
Substance index (1):
Substance index
Chemical Substance indexed to the Article.
Reference (4):
  • Tournigand C, Cervantes A, Figer A, et al: OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-A GERCOR study. J Clin Oncol 24(3): 394-400, 2006.
  • Goebel FM, Liedo G, Chibaudel D, et al: Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study. ASCO Annual Meeting, J Clin Oncol 25 (18S): abstr 4013, 2007.
  • André T, Boni C, Mounedji-Boudiaf L, et al, Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment of colon cancer. N Engl J Med 350(23): 2343-2351, 2004.
  • André T, Boni C, NavarroM, et al: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27(19): 3109-3116, 2009.
Terms in the title (4):
Terms in the title
Keywords automatically extracted from the title.

Return to Previous Page